Company / Working Capital
Fulgent Genetics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$465.5M
FY2025
5-year range
$280.7M / $539.8M
FY2021-FY2025
Trend
+65.9%
vs FY2024
Sector context
#66 of 160
Health Care
What the data says
At $466M, Fulgent Genetics, Inc.'s working capital ranks #66 of 160 in the Health Care sector. Working Capital returned to growth in FY2025 after 2 years of decline, reaching $466M.
Based on SEC 10-K filings.
$466M in FY2025 with a 5-year CAGR of +3.4%.
Improved from $435M to $466M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -4.8%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Sector benchmark
#66 of 160 in Health CareTop 41% of 160This company $465.5M Sector average $757.1M
▼
-38.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, working capital increased 65.9% year-over-year.
- Ranks #66 out of 160 companies in the Health Care sector.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $465.5M | +65.9% |
| FY2024 | $280.7M | -35.5% |
| FY2023 | $434.8M | -19.4% |
| FY2022 | $539.8M | +6.5% |
| FY2021 | $506.6M | +28.8% |
| FY2020 | $393.5M | +1079.7% |
| FY2019 | $33.4M | -9.4% |
| FY2018 | $36.8M | +23.0% |
| FY2017 | $29.9M | +31.1% |
| FY2016 | $22.8M | +917.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026